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Context. Immunohistochemical stains for p53 are used as a diagnostic marker associated with malignancy in several histologic
types of salivary gland tumors. This marker may be useful in diﬀerentiating pleomorphic adenoma (PA) from carcinoma ex
pleomorphic adenoma (CPA), as these tumors are often diﬃcult to distinguish on the basis of morphology alone. Objective.t o
evaluatewhateverinactivationoftumorsuppressorgene(p53)increaseswiththetumorprogressionfromnormalsalivarytissueto
PA and eventually CPA. Design.P a r a ﬃnblocks of 29 cases of PA, which were surrounded by normalparotid gland, and 27 cases of
carcinomaex pleomorphicadenomawere retrieved andvalidated. Inallcasesofcarcinomaex pleomorphicadenoma,aPA “ghost”
was identiﬁed, and the malignant element was either undiﬀerentiated carcinoma or adenocarcinoma. Results. The results showed
negative nuclear expression of P53 in normal parotid gland. Nuclear P53 was expressed strongly in 6/29 (20.7%) pleomorphic
salivary adenoma and 10/27 (37%) carcinoma ex pleomorphic adenoma. Conclusion. Our data suggest that inactivation of p53
may play an important role in the evolutionof pleomorphic salivary adenoma and carcinoma ex pleomorphic adenoma.
1.Introduction
Pleomorphic salivary adenoma (PA) is the most common
neoplasm ofsalivary glands [1] and was shown sometimes to
undergo malignant transformation in its natural course [2].
Carcinoma ex pleomorphic adenoma (CPA) is considered to
be a malignant transformation product of pre-existing pleo-
morphic adenoma [3]. CPA is the most common malignant
mixed tumor and has been estimated to account 10% of all
salivaryglandmalignancy[4].Thepathogeneticmechanisms
involved in the progression of pleomorphic adenoma to a
carcinomaremain unclear,requiringevaluationofmolecular
events in both pleomorphic adenoma and carcinoma arising
in pleomorphic adenomas [5]. The current studies of the
molecular biology of cancers have demonstrated that the
loss of function of tumor suppressor gene such as p53 may
lead to the development of many diﬀerent cancer types
[6, 7]. The published literature on tumor markers in CPA is
limited due to the fact that these tumors are rare. Mutation
of P53 tumor suppressor gene, located on the short arm
of chromosome 17, is among the most commonly detected
genetic abnormalities in human neoplasia.
Our study aimed to characterise the alterations and
aberrations intheexpression ofp53and toevaluatewhatever
inactivation of tumor suppressor gene (p53) increases with
the tumor progression from normal salivary tissue to PA and
eventually CPA.
2.Materialsand Methods
Archived formalin-ﬁxed, paraﬃn-embedded tissue blocks
of 29 cases of pleomorphic adenomas, and 27 cases of
carcinoma ex pleomorphic adenoma were obtained from
the Department of Oral Pathology at Aleppo Dental School
(Tables 1 and 2). Normal tissue of the salivary gland
surrounding the tumor was used as a control in 29 cases of
pleomorphic adenoma. The immunohistochemical expres-
sion of antibodies against p53 was examined in the selected
cases.2 Journal of Cancer Epidemiology
Table 1: Clinical data of pleomorphic adenomas cases.
Case Age Gender Gland type
18 7 FP a r o t i d g l a n d
25 2MP a r o t i d g l a n d
36 3MP a r o t i d g l a n d
44 8 FP a r o t i d g l a n d
57 6 FP a r o t i d g l a n d
64 7MP a r o t i d g l a n d
76 2 FP a r o t i d g l a n d
83 3MP a r o t i d g l a n d
94 9 FP a r o t i d g l a n d
10 45 M Parotid gland
11 63 F Parotid gland
12 53 F Parotid gland
13 27 F Parotid gland
14 59 F Parotid gland
15 33 F Parotid gland
16 55 F Parotid gland
17 26 F Parotid gland
18 65 F Parotid gland
19 40 M Parotid gland
20 57 M Parotid gland
21 34 M Parotid gland
22 74 F Parotid gland
23 67 F Parotid gland
24 32 M Parotid gland
25 31 M Parotid gland
26 62 F Parotid gland
27 76 F Parotid gland
28 21 F Parotid gland
29 61 F Parotid gland
2.1. Inclusion Criteria for Carcinoma Ex Pleomorphic Ade-
noma. According to the World Health Organization histo-
logicalclassiﬁcation published in 2005,malignant changes in
the PA include three diﬀerent types: CPA, carcinosarcoma,
and metastasizing PA.
The proposed criteria for deﬁning carcinoma ex pleo-
morphic adenoma by Nagao et al. [8] were used to select and
reclassify our cases of carcinoma ex pleomorphic adenoma.
The use of strict pathological criteria may underesti-
mate the frequency of carcinoma ex pleomorphic adenoma
because the malignant cells in some cases may obliterate the
original pleomorphic adenoma.
The Inclusion criteria for carcinoma ex pleomorphic
adenoma includes the following:
(i) Majorglandprimary lesion (parotid orsubmandibu-
lar), and the macroscopic features that suggest
malignant transformation in pleomorphic adenoma
include poorly deﬁned and/or inﬁltrative tumor
margins, the presence of foci of hemorrhage, and
necrosis.
(ii) The existence of benign and malignant elements are
considered as well.
(iii) Benign element can be pleomorphic adenoma within
thetumormass, biopsyprovenhistory ofpreviousPA
(pleomorphic adenoma) indicated that it was in the
same location as the subsequent carcinoma.
(iv) Malignant elements can be undiﬀerentiated carci-
noma, adenocarcinoma, and multiple patterns of
diﬀerentiation including undiﬀerentiated or adeno-
carcinoma patterns.
2.2. Exclusion Criteria for Carcinoma Ex Pleomorphic Ade-
noma. The exclusion criteria for carcinoma ex pleomorphic
adenoma includes the other well-recognized salivary carci-
nomas and those of uncertain type included in the current
WHO histological classiﬁcation of tumors [9].
All specimens using hematoxylin and eosin slides were
reviewed by two pathologists to conﬁrm the histopatho-
logical diagnosis and to reclassify the studied cases. The
carcinoma cases classiﬁed according to the above-mentioned
criteria as undiﬀerentiated carcinoma or adenocarcinoma.
The Research Ethics Committee at Aleppo Dental School
provided a favourable ethical opinion (Ref: 145/2010).
2.3. Immunohistochemistry. Paraﬃn-embedded, 4-μm-thick
tissue sections from all 55 specimens were cut. The sections
were deparaﬃnized in xylene and dehydrated through
graded alcohols. Sections were processed used streptavidin-
biotin-peroxidase method. Brieﬂy, the endogenous peroxi-
dase was blocked by 3% hydrogen peroxidase for 5minutes
followed by TBS wash. Nonspeciﬁc immunoreactivity was
blocked by incubation with normal goat serum for 20
minutes. A primary antibody TP53 monoclonal mouse anti-
human (clone,D-O7: Dako) was dilutedto 1:25 (40μL/mL)
in tris buﬀer saline (TSA) containing 0.1% bovine serum
albumin for 2 hours at room temperature. All sections were
washed by TBS for 5 minutes. Sections were incubated
with the biotinylated secondary antibody reagent for 30
minutes followed by (TBS) wash for 5 minutes. Slides were
incubated with streptavidin and horseradish peroxidase for
30 minutes followed by (TBS) tris buﬀer saline wash for 5
minutes. Incubate with a prepared chromogenic substrate
solution (Diaminobenzidine) for 15 minutes. Sections were
counterstainedwith0.25%methylgreenindistilledwaterfor
5 minutes. Sectionswere dehydrated and mounted in Depax.
Squamous cell carcinoma was used as positive control.
Negative control was used only with substitution of the
primary antibody with TBS. The percentage of P53-positive
nuclei was semiquantitatively assessed by two independent
observers and scored as negative (0) no expression of nuclear
protein, (1) weak staining 0–25% of the total cells shows
positive staining in the nucleus, (2) moderate staining >25–
75% of the total cells in the test area show positive nuclear
staining, (3) strong staining >75–100% cells show positive
nuclear staining.
2.4. Statistical Analysis. Cells of the carcinomatous com-
ponent of the CPA were always scored. The statistical
analysis included the use of descriptive statistics, frequen-
cies/proportion, and crossed tabulation. Also, statisticalJournal of Cancer Epidemiology 3
Table 2: Clinical data of cases from carcinomas ex pleomorphic adenomas.
Case Age Gender Gland Histological subtype Metastasis to lymph nodes∗
1 77 F Parotid Adenocarcinoma Yes
2 28 M Parotid Adenocarcinoma No
3 78 M Submandibular Undiﬀerentiated Yes
44 5M P a r o t i d U n d i ﬀerentiated Yes
57 6 F P a r o t i d U n d i ﬀerentiated No
68 2 F P a r o t i d U n d i ﬀerentiated No
7 71 M Parotid Adenocarcinoma No
8 67 M Submandibular Undiﬀerentiated Yes
9 63 M Submandibular Undiﬀerentiated Yes
10 55 M Submandibular Undiﬀerentiated Yes
11 73 M Parotid Undiﬀerentiated Yes
12 71 M Parotid Undiﬀerentiated No
13 64 M Parotid Undiﬀerentiated Yes
14 60 F Parotid Undiﬀerentiated Yes
15 49 F Submandibular Undiﬀerentiated No
16 39 F Parotid Undiﬀerentiated Yes
17 56 M Parotid Undiﬀerentiated No
18 45 F Parotid Undiﬀerentiated Yes
19 57 M Parotid Undiﬀerentiated Yes
20 66 F Parotid Undiﬀerentiated No
21 86 F Submandibular Undiﬀerentiated Yes
22 17 F Parotid Undiﬀerentiated No
23 78 M Submandibular Undiﬀerentiated Yes
24 26 M Parotid Undiﬀerentiated No
25 31 F Parotid Undiﬀerentiated No
26 71 M Parotid Undiﬀerentiated No
27 71 M Parotid Undiﬀerentiated No
∗Metastasis to lymph nodes at the time of tumor resection.
Table 3: p53 expression of nuclear staining in the nontumor duct
cells.
p53 pattern Frequency Percent
Negative staining 12 41.4
Weak staining 13 44.8
Moderate staining 3 10.3
Strong staining 1 3.4
Total 29 100.0
analyses, includingMann-Whitney and Wilcoxon’snonpara-
metric tests, were performed on the data. All statistical tests
were two sided and P-values less than .05 were considered to
be statistically signiﬁcant.
3.Results
3.1. p53 Expression in the Normal Tissue of Salivary Gland
Surrounding the Pleomorphic Adenoma. Three components,
duct, acinar cells, and stroma were examined in the normal
tissue adjacent to the pleomorphic adenoma Figure 1.W e
evaluated the percentage of p53-positive cells in each case,
Table 4: p53 expression of nuclear staining in acinar cells
surrounding the tumor of pleomorphic adenoma.
P53 pattern Frequency Percent
Negative staining 24 82.8
Weak staining 4 13.8
Moderate staining 1 3.4
Total 29 100.0
with the use of the frequency test. The results in Table 3
(nuclear staining of nontumor duct cells) indicated that p53
showed strong positive staining in 1 (3.4%) case out of 29,
3 (10.3%) cases with moderate staining, 13 (44.8%) cases
with weak staining, and 12 (41.4%) cases had no expression
(Table 3)whereas expression ofp53cytoplasmicstaining was
presentinnontumorductcellsasfollows:3(10.3%)casesout
of 29 with moderate staining, 9 (31.0%) with weak staining,
and 17 (58.6%) with negative staining.
p53 (nuclear staining of the acinar cells) showed negative
staining in 24 (82.8%) cases out of 29, 4 cases with weak
staining and 1 (3.4%) case with moderate staining (Table 4).4 Journal of Cancer Epidemiology
Figure 1: Showing negative nuclear staining of p53 in normal
salivary tissue. Original magniﬁcation x40.
p53 (nuclear staining in stroma) was observed in 1
(3.4%) case out of 29 with strong staining, 8 (27.6%) cases
with weak staining, and 20 cases (69.0%) with negative
staining (Table 5).
The results showed in those tables that p53 expression
was negative or low with positive nuclear staining in most
elements of the control group (duct, acinar cells, and
stroma).
3.2. p53 Expression in Pleomorphic Adenoma. p53 was
strongly expressed in tumor duct cells in 6 (20.7%) cases
out of 29. 16 (55.2%) cases showed moderate staining,
and 7 (24.1%) cases expressed weak staining (Table 6). The
expression of p53 in pleomorphic adenoma was shown in
Figures 2, 3,a n d4.
p53 nuclear staining in the myxochondroid tissue was
identiﬁed in 1 (3.4%) case with strong staining, 10 (34.5%)
cases with moderate staining, and 18 (62.1%) cases with
weak staining (Table 7).
The p53 expression in pleomorphic adenoma was clar-
iﬁed in cross-tabulation tables (Table 8) to compare p53
expression in myxochondroid and duct cells.
Wilcoxon’s test showed signiﬁcant diﬀerences between
p53 expression of p53 nuclear staining in myxochondroid
and tumor duct cells, P value < .001).
3.3. p53 Expression in Carcinoma Arising in Pleomorphic
Adenoma. p53 was strongly expressed in carcinoma cells
in 10 (37%) cases out of 27. Moderate staining was seen
in 2 (7.4%) cases and 15 (55.6%) cases expressed negative
staining Figures 5, 6, 7,a n d8.
3.4. Comparison between p53 Expression in Pleomorphic
Adenoma and Carcinoma Arising in Pleomorphic Adenoma.
The Mann Whitney test showed no signiﬁcant diﬀerence
between p53 expression in pleomorphic adenoma (tumor
duct cells) and carcinoma arising in PA (P value .08 > .05).
6 cases out of 29 showed strong p53 staining in tumor duct
Figure 2: Showing strong p53 staining in pleomorphic salivary
adenoma. Original magniﬁcation x40.
Figure 3: Showing moderate p53 staining in pleomorphic salivary
adenoma. Original magniﬁcation x40.
Table 5: p53 expression of nuclear staining in stroma (normal
tissue surrounding the tumor) in pleomorphic adenoma.
p53 pattern Frequency Percent
Negative staining 20 69.0
Weak staining 8 27.6
Strong staining 1 3.4
Total 29 100.0
Table 6: p53 expression in the nucleus of the tumor duct cells.
p53 pattern Frequency Percent
Weak staining 7 24.1
Moderate staining 16 55.2
Strong staining 6 20.7
Total 29 100.0
cells inpleomorphic adenoma, but10 cases outof27 showed
the same expression in carcinoma cells.Journal of Cancer Epidemiology 5
Figure 4: Showing low nuclear staining of p53 in pleomorphic
salivary adenoma.Original magniﬁcation x40.
Table 7: p53 expression of the nucleus staining in myxochondroid
(tumor area).
p53 pattern Frequency Percent
Weak staining 18 62.1
Moderate staining 10 34.5
Strong staining 1 3.4
Total 29 100.0
Table 8: Cross-tabulation p53 nuclear staining in myxochondroid
tissue and duct cells of pleomorphic adenoma.









Weak staining 6 12 0 18
Moderate staining 1 4 5 10
Strong staining 0 0 1 1
Total 7 16 6 29
p53 expression in either pleomorphic adenoma or car-
cinoma cases arising in pleomorphic adenoma is shown in
Figures 2–7.
4.Discussion
4.1. p53 and Normal Tissue of the Salivary Glands. p53
expressed negative or weak nuclear staining in normal
salivary glands (duct and acinar cells of the control group),
and these results are consistent with Deguchi et al. [10]w h o
stated that no p53 immunostaining was found in the normal
salivary gland tissues.
Soini et al. [11] mentioned that the p53 wild-type
protein had a short half life less than the p53 mutated
protein allowing p53 mutated protein to be detected in
Figure 5: Showing strong p53 staining of nuclei in CPA. Original
magniﬁcation x40.
Figure 6: Showingmoderate p53 nuclear staining in CPA. Original
magniﬁcation x40.
the cells. The authors of [12] observed that there is no
evidence that normal thymic epithelial cells expressed p53.
Ogden et al. [13] studied p53 expression in specimens from
normal, benign oral mucosa. Biopsies were obtained from
54 specimens of nonmalignant tissues (normal mucosa,
lichen planus, popillomas, keratosis). p53 protein was not
observed in the above lesions. Ogden et al. [14] detected
overexpression of p53 in normal oral mucosa of oral cancer
patients. The p53 positivity in normal mucosa may be due
to stabilization of the wild-type p53. The tumor suppressor
proteinp53is present ina wide variety ofcells. In thenormal
cell, the concentration of wild-type p53 protein is generally
below the detection level of immunohistochemical methods.
H o w e v e r ,i nt h eg e n ec o d i n gf o rt h ep 5 3p r o t e i n ,p o i n t
mutation occurs frequently, leading to the accumulation of
mutant protein. Thus, in 22–70% of malignancies such as
cancer in the colon, stomach, bladder, breast, lung, thyroid,
p53 protein can be demonstrated by immunohistochemistry
[15, 16].
It is concluded that wild-type p53 in normal tissues
is generally not detectable by immunochemistry, owing6 Journal of Cancer Epidemiology
Figure 7: Showing low nuclear staining of p53 in CPA. Original
magniﬁcation x40.
to a combination of low expression and short half life.
Mutation of the p53 gene results in a conformation change
in the protein, which becomes stabilised, thus allowing for
immunohistochmical detection.
4.2. p53, Pleomorphic Adenoma and Carcinoma Arising in
Pleomorphic Adenoma. p53 strong and moderate nuclear
staining was classiﬁed as positive, and the indicator for
existing alteredp53 in pleomorphic adenoma and carcinoma
arising in PA. Low and negative nuclear staining was
classiﬁed as negative, and the indicator for existing wild-type
(nonaltered p53). The proportion of p53-positive nuclear
stained cells (strong and moderate) was (75.9%) in tumor
duct cells of pleomorphic adenoma cases (22 cases out of
29 expressed strong or moderate staining). These results
are consistent with Azuma et al. [17]w h of o u n dp 5 3
accumulation in 75% (3/4) of pleomorphic adenoma cell
lines (using Ab 1801 and Ab 2401 antibodies). Deguchi
et al. [10] found that six cases out of 33 (18%) with
benign pleomorphic adenoma were p53 positive (using
the CM-1 antibody). Yamamoto et al. [5]a n a l y s e dt i s -
sue specimens containing three morphological components
including adenoma, transitional foci, and carcinoma for 8
cases of carcinoma arising in pleomorphic adenoma. The
immunohistochemical analysis of p53 protein (using ab-6,
clone DO-1 antibody) revealed that p53 was expressed in
only one case (13%) out of 8 of pleomorphic adenoma. Li et
al. [18] analyzed the numeric aberrations of chromosome 17
and p53 gene deletion in pleomorphic adenoma. Monosomy
17 was shown in (29.6%) ofpleomorphic adenoma cells. p53
was expressed in 2 out of 75 cases of pleomorphic adenoma.
They conﬁrmed that chromosome aberrations started early
in pleomorphic adenoma.
Yamamoto et al. [19] found no mutations in p53
observed in the 7 cases of pleomorphic adenoma (control
group). Nordkvist et al. [20] studied p53 expression (using
Do-7 antibody) in 68 cases of benign pleomorphicadenoma.
Only 8 cases out of 68 expressed p53 with weakly positive
staining. Gallo et al. [21] found that three cases showed
Figure 8: Showingp53 negative control for CPA. Original magniﬁ-
cation x40.
positive p53 (11%) in benign parotid gland tumors out of
26 cases. K¨ arj¨ ae ta l .[ 22] reported that p53 expression (using
Ab 1801) was expressed in 41% of pleomorphic adenomas.
The results of carcinoma arising in pleomorphic ade-
noma showed that 12 cases (44.4%) expressed moderate or
strong staining of p53. This is comparable to the frequencies
of 67% [10] and 75% [5], reported previously. Li et al. [18]
studied the numeric aberrations of chromosome 17 and p53
gene deletion carcinomas arising in pleomorphic adenoma.
Polysomy was observed in 19.6% of carcinoma cells, and
monosomy17wasshownin(30.8%)ofCPAcells(carcinoma
in pleomorphic adenoma). Immunohistochemical staining
showed p53 was expressed in 6 out of 9 CPA cases (66.7%).
Yamamoto et al. [19] found a high rate of mutations
(loss of heterozygosity) as the p53 gene was detected in
cases of carcinoma arising in pleomorphic adenoma (58%).
Nordkvist et al. [20] studied 24 cases of carcinoma ex
pleomorphic adenoma. 17 cases showed p53 expression. 9
cases with positive p53 staining had 1–10% of positive cells,
5 cases showed positive p53 staining in 11–50% of the cells,
and 3 cases showed very strong staining of p53 in 51–100%
of the cells.
K¨ arj¨ ae ta l .[ 22] studied 12 cases of carcinoma arising in
PA, 6 (50%) cases showed p53-positive nuclear staining.
4.3. p53 Strong Nuclear Staining as a Strong Indicator
for Altered p53. If we considered the p53-positive strong
staining alone as a strong indicator for altered p53 (>75–
100 positive cells), then, the results would show that p53
was expressed strongly in 6 (20.7%) cases (tumor duct
cells) out of 29 in pleomorphic adenoma but in 10 cases
(37%) out of 27 cases of carcinoma arising in PA. The
results demonstrated that the incidence of p53 alteration
increased from pleomorphic adenoma to carcinoma arising
in pleomorphic adenoma.
The results showed the progressive alteration of p53
expression in pleomorphic adenoma, in a progression to
carcinoma arising in PA. It is likely that transcription of a
mutated protein that accumulated in the nucleus and wasJournal of Cancer Epidemiology 7
readily detected immunohistochemically accounted for the
majority of these cases.
4.4. The Interpretation of the Variations in the Detection of
p53 Staining. This diﬀerences in the expression of p53 in
ourstudy and the othersmentioned above may have resulted
from the following reasons.
(1) The use of diﬀerent antibodies.
(2) Diﬀerent classiﬁcations, for example, (0 = negative
staining, 1 = low, 2 = moderate, 3 = strong or 0–
3 = negative and 4 = positive or 0–2 = negative, and
3–4 = positive or negative and positive staining).
(3) Fixation times and concentrations of antibodies.
(4) The sensitivity of the technique used.
Mutation is usually increased as cells progress from benign
tumortocarcinoma. Itwassurprising thattheresultsshowed
that the proportion of altered p53 in pleomorphic adeno-
mas was higher than in carcinoma cases after combining
moderate and strong staining together, and negative and
low staining together. If only strong positive staining was
used as indicator for the alteration in the expression of
tumor suppressor protein p53, then alteration in expression
of p53 was increased in pleomorphic adenoma compared to
carcinoma arising in pleomorphic adenoma.
Immunostaining technique has been used only to detect
the alteration of expression of p53 in our study. This tech-
nique is an easy method to carry out, but the assessment of
the positive or negative nuclear staining cells is controversial.
Many authors used diﬀerent criteria, so the results cannot
be compared. In the present study, the use of negative
and positive staining for the assessment of staining avoided
any confusion in the interpretation of the results. Ideally
the immunostaining technique is used only combined with
anothertechniqueforexample,(PolymeraseChainReaction,
Western Blotting) to detect and conﬁrm existence of a
mutation. Many studies used criteria such as negative, low,
moderate, and strong staining.
4.5. Expression of p53 in the Tumor Duct Cells and Myxo-
chondroid Tissue in Pleomorphic Adenomas. Wilcoxon’s test
showedasigniﬁcant diﬀerencebetweenp53expressionofthe
nuclear staining in myxochondroid and tumor duct cells, (P
value < .001).
p53expression in pleomorphicadenoma showed thatthe
incidenceof aberrant expression ofthese proteinswas higher
in tumor duct cells than in myxochondroid tissue. Although
p53 showed alteration in expression in myxochondroid
tissue, there is evidence that cells in myxochondroid tissue
show low levels of proliferation [23].
4.6. Comparative Statistical Analysis of p53 in Pleomorphic
Adenoma and Carcinoma Arising in Pleomorphic Adenoma.
The Mann Whitney test showed no signiﬁcant diﬀerence
between p53 expression in pleomorphic adenoma (tumor
duct cells) and carcinoma arising in PA (P value > .05).
Unfortunately, p53 cannot be used as indicator to diﬀeren-
tiate between pleomorphic adenomas and carcinoma arising
in PA.
5.Conclusion
The conclusion can be summarised in the following points.
(i) The sample of carcinoma arising in pleomorphic
adenoma cases is large (27 cases) compared with
others,thoughfurther research isrequiredtoincrease
t h es a m p l es i z et od e t e r m i n et h er o l eo ft u m o r
suppressor proteins in the pathogenesis of malignant
transformation of pleomorphic adenoma.
(ii) p53 was altered in PA and with increased frequency
in CPA.
(iii) The use of one criterion as positive and negative
nuclear staining to assess the expression of tumor
suppressor proteins appears to give more convincing
results than the use of diﬀerent categories such as
negative, low, moderate, and strong staining.
(iv) The tumor suppressor protein p53 shows aberrant
expression in tumor duct cells more frequently than
cells in myxochondroid tissue, consistent with the
concept that the latter may not be the stem tumor
cells responsible for malignant progressions.
(v) Expression of p53 is altered in PA and CPA. Further
research to extract DNA from the studied cases
to detect mutations as a probable main cause of
inactivation and to identify other causes of inactiva-
tion such as methylation or loss of heterozygosity is
recommended.
Abbreviations
PA: Pleomorphic salivary adenoma
CPA: Carcinoma ex pleomorphic adenoma.
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